are added to the solution and dissolved therein the concentration of compound a is 0 0001 to 5 w v preferably 0 0001 to 0 001 w v and most preferably about 0 0005 w v based on the sterilized purified water after dissolution the ph is adjusted with a ph controller to be within a range suitable for use as an ophthalmic medicine preferably within the range of 4 5 to 8 sodium chloride glycerin mannitol or the like may be used as the isotonic agent p hydroxybenzoic acid ester benzalkonium chloride or the like as the preservative sodium hydrogenphosphate sodium dihydrogenphosphate boric acid or the like as the buffering agent sodium edetate or the like as the stabilizer polyvinyl alcohol polyvinyl pyrrolidone polyacrylic acid or the like as the viscous vehicle and sodium hydroxide hydrochloric acid or the like as the ph controller if required other ophthalmic drugs such as epinephrine naphazoline hydrochloride berberine chloride sodium azulenesulfonate lysozyme chloride glycyrrhizate and the like may be added the eye drops produced by the above method typically need only be applied to the eyes a few times a day in an amount of one to several drops at a time though in more severe cases the drops may be applied several times a day a typical drop is about 30 u03bcl according to the method of the present invention ophthalmic formulations containing compound a are used to inhibit pro inflammatory cytokine secretion from human ocular cells such as human conjunctival epithelial cells this type of cytokine secretion e g il 6 and il 8 can stimulate ocular neovascularization see for example yoshida et al iovs 39 1097 1998 and other non allergic inflammatory conditions such as dry.